 |
 |

Membrane Attack Complex Deposits in Cutaneous Lesions of Dermatomyositis
José M. Mascaró, Jr, MD;
Gisela Hausmann, MD;
Carmen Herrero, MD;
Josep M. Grau, MD;
Maria C. Cid, MD;
José Palou, MD;
José M. Mascaró, MD, MS
Arch Dermatol. 1995;131(12):1386-1392.
Abstract
 |  |
Background and Design The presence of membrane attack complex of complement (MAC) deposits in the intramuscular vasculature of biopsy specimens taken from patients with dermatomyositis (DM) has been implicated in the pathogenesis of this myopathy. The purpose of this study was to investigate the presence of MAC deposition in the skin lesions of patients with DM. Using immunohistochemical methods, we examined 22 biopsy specimens from lesional skin, six biopsy specimens from uninvolved skin, and 12 muscle biopsy specimens from patients with DM for the presence of MAC and vitronectin and CD59, two regulatory proteins of complement.
Results The deposition of MAC was demonstrated in a large percentage of biopsy specimens obtained from the lesional skin of patients with DM. Deposits were found along the dermoepidermal junction in 19 (86%) of 22 biopsy specimens. Deposits on the vessel walls of the dermis were found in 17 (77%) of 22 biopsy specimens; but only in six of these biopsy specimens (27%) were deposits present in more than 10% of blood vessels. In contrast, deposits along the dermoepidermal junction and the vessel walls of the dermis were absent in specimens from uninvolved skin. In 12 muscle biopsy specimens obtained simultaneously from these patients, MAC deposits were found on the vessel walls in nine (75%), but only in six (50%) were deposits found in more than 10% of the intramuscular vessels. The pattern of vitronectin immunoreactivity in skin and muscle biopsy specimens obtained from patients with DM was similar to MAC deposits. The expression of CD59 was normal in all skin and muscle biopsy specimens.
Conclusions The deposition of MAC was found in a high percentage of biopsy specimens from the lesional skin of patients with DM; it was absent in uninvolved skin. These findings suggest that the complement system may be involved in the pathogenesis of the skin lesions of DM.
(Arch Dermatol. 1995;131:1386-1392)
Author Affiliations
From the Departments of Dermatology (Drs Mascaró, Jr, Hausmann, Herrero, Palou, and Mascaró) and Internal Medicine (Drs Grau and Cid), Hospital Clínico, Barcelona, Spain. Dr Mascaró, Jr, is now with the Department of Dermatology, Medical College of Wisconsin, Milwaukee.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
A Pilot Trial of Rituximab in the Treatment of Patients With Dermatomyositis
Chung et al.
Arch Dermatol 2007;143:763-767.
ABSTRACT
| FULL TEXT
Complement Activation Promotes Muscle Inflammation during Modified Muscle Use
Frenette et al.
Am. J. Pathol. 2000;156:2103-2110.
ABSTRACT
| FULL TEXT
Prospects for UV-Al therapy as a treatment modality in cutaneous and systemic LE
McGrath
Lupus 1997;6:209-217.
|